Document is current
Any future updates will be listed below
-
Authors
Liu, Ping
Lin, Bingjiang
Shen, Yanna
Lu, Yonghong
Li, Jingyi
Lv, Dong
Yao, Xu
Man, Xiaoyong
Fang, Hong
Jiang, Guan
Yu, Nan
Liu, Dongmei
Zhan, Siyan
Zhang, Jianzhong https://orcid.org/0000-0002-5485-682X
-
Funding
Funding for this research was provided by:
Sanofi China Investment Company
Chinese Association of Rehabilitation Medicine
- License Information
-
More Information
Article History
Received: 12 May 2025
Accepted: 2 September 2025
First Online: 19 September 2025
Declarations
:
: Jianzhong Zhang is a consultant for and has received honoraria from Pfizer Investment Co Ltd, Novartis Pharmaceuticals (China), Sanofi China, LEO Pharma (Shanghai) Co Ltd, GSK (China) Investment Co Ltd, Eli Lilly and Company (China), Xi’an Jassen Pharmaceutical Ltd, Bristol-Myers Squibb (China) Investment Co Ltd, Beijing Wenfeng Tianji Pharma Ltd, Keymed Biosciences (Chendu) Ltd, Akeso Biopharma Co Ltd, Reistone Biopharma Co Ltd and Kintor Pharmaceutical Ltd. Ping Liu, Bingjiang Lin, Yanna Shen, Yonghong Lu, Jingyi Li, Dong Lv, Xu Yao, Xiaoyong Man, Hong Fang, Guan Jiang, Nan Yu, Dongmei Liu and Siyan Zhan have nothing to disclose.
: The study protocol was approved by the Ethics Committee of the Peking University People’s Hospital (approval no. 2021PHB076-001; 7 April 2021) and the local ethics committees at other sites. The study was conducted in accordance with ethical principles that have their origins in the Declaration of Helsinki and that are consistent with International Conference on Harmonisation/Good Clinical Practice, applicable regulatory requirements, and the sponsor’s bioethics and human biospecimen policies. All patients or their legal guardians provided written informed consent to participate in the study.
